LB Pharmaceuticals names Susan Kozauer as chief medical officer
The neuromedicines company said the hire comes as it heads toward Phase 3 NOVA-2 schizophrenia trial results in the first half of 2027.
SEC filing
Latest
5 stories
Tuesday, September 15
Thursday, September 3
LB Pharmaceuticals names Joseph Miller as chief financial officer
The neuromedicines company said Miller starts as CFO effective September 2, 2026, ahead of pivotal NOVA-2 trial results for LB-102 in schizophrenia.
SEC filing
Tuesday, August 11
LB Pharmaceuticals moves up NOVA-2 schizophrenia readout to first half of 2027
The company also detailed plans to expand LB-102 into new neuropsychiatric indications and reported $327.8 million in cash as of June 30, 2026.
SEC filing
Wednesday, July 29
LB Pharmaceuticals sets $150 million private placement of stock and warrants
The neuromedicines company will sell shares and pre-funded warrants to institutional investors to expand its LB-102 pipeline into new indications.
SEC filing
Wednesday, July 22
LB Pharmaceuticals moves up NOVA-2 schizophrenia trial readout to first half of 2027
The company cited faster-than-expected enrollment as the reason for pulling forward its Phase 3 timeline for LB-102.
SEC filing